Browse by Audience
Skip to content
Papers of the Week
Real-world effectiveness and safety of tildrakizumab in long term-treatment of plaque psoriasis: Results from the non-interventional, prospective, multicenter study TILOT.
Abstract
Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) is an IL-23 inhibitor licensed for moderate-to-severe plaque psoriasis. Regulatory approval of medicinal products is based on safety and efficacy data from randomized controlled trials (RCTs) which impose stringent selection criteria. Long-term non-interventional studies (NIS) are needed to establish effectiveness and safety in daily practice bridging the gap between RCTs and the real-world setting.